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Abstract 
BACKGROUND: Rheumatoid arthritis (RA) is the most common chronic disease involving joints. Anti-cyclic 
citrullinated peptide (anti-CCP) as a specific antibody is a reliable index to early diagnosis of RA. Disease-modifying 
anti-rheumatic drugs (DMARDs) can reduce progression of RA joint destruction. The present study aimed to 
investigate the effects of DMARDs in reducing serum anti-CCP. 
METHODS: A cross-sectional study was performed on 30 patients including 22 females and 8 males RA patients 
according to the American College of Rheumatology (ACR) classification criteria, who referred to the Rheumatology 
Clinic. Treatment with DMARD group started at the beginning of the study (May 2009). At 1st and 6th month of the 
study, clinical findings and disease activities were recorded and anti-CCP was measured. 
RESULTS: At the beginning and the end of the study, morning stiffness for more than 1 h and involvement of three 
areas were, 28 (93%) and 12 (40%), respectively. Indicators of disease severity in patients, the mean ± SD serum 
levels of erythrocyte sedimentation rate at the beginning and end, were 40.7 (30-59) mm/1 h and 13.4 (9-86) 
respectively. Anti-CCP at the beginning and end of the study was 141.83 (65.8-101.09) U/ml and 65.8 (62-92) 
U/ml respectively (P < 0.05). Disease Activity Score in 28 joints and rheumatoid factor positive and C-reactive 
protein positive were significantly different at the onset and at the end of the study (P < 0.05). 
CONCLUSION: Measurement of serum anti-CCP is a helpful index of treatment response and monitoring of 
treatment efficacy in patients with RA. 
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Introduction1 




Rheumatoid arthritis (RA) is a chronic 
inflammatory disease in which the Synovium 
tissue can be attacked more than any other 
organs. Despite of increased medical costs, the 
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quality of life is impaired in many patients 
clearly. The American College of Rheumatology 
(ACR) criteria usually is used for classification of 
RA,1 which does help neither early diagnosis nor 
determination the severity of disease. Laboratory 
tests can lead to fast diagnosis. Measurement of 
anti-cyclic citrullinated peptide (anti-CCP) 
antibodies besides other antibodies such as 
prinuclease antibodies, anti-cratin antibody, anti-
filagrin antibody can confirm the diagnosis.2,3 
The current blood marker is rheumatoid factor 
(RF), anti-Fc fragment of IgG, which is neither 
specific nor sensitive enough for diagnosing RA. 
RF titer in the early stages of the disease may not 
be sufficient enough for the diagnosis and disease 
prognosis. Therefore, treatments based on this 
finding may not be enough. Finding a marker that 
indicate rheumatoid arthritis diagnosis at early 
stages, could be helpful for prognosis and 
monitoring of responses to the treatment.4 
Citrulline, as an unusual amino acid, is produced 
by an enzymatic reaction of arginine. It is as a part 
of the protein building such as filagrin and 
profilagrin. During cell differentiation process, 
this protein will be produced. In RA patients, 
anti-CCP antibodies are synthesized against this 
atypical protein. Anti-CCP measurement is a 
method for determining the prognosis of arthritis 
because it accompanies with more destructive 
forms of RA. Anti-CCP test has a high sensitivity 
and specificity and it is checked via enzyme-
linked immunosorbent assay (ELISA) and using 
patients, serum.5 
Several studies have pointed out the positive 
predictive value of anti-CCP for prognosis of RA. 
However, it has also been found in approximately 
1.5% of healthy people and in the people with 
other joint diseases.6 The disease-modifying anti-
rheumatic drugs (DMARDs) group is one of the 
five group therapies that have been used in the 
treatment of rheumatoid arthritis. DMARDs 
including a group of drugs that are structurally 
uniform. Their common characteristic is slowing 
down the progression of the disease. They have 
been accepted as the basis of the treatment of RA.7 
Anti-CCP levels are increasing in early RA 
disease leading to joint destruction.8 There are 
several evidences showing that increased levels of 
anti-CCP are correlated with progression of 
radiological joint damage.9,10 
Several studies have mentioned the relation 
between serum anti-CCP and DMARD therapy, 
but they have found some conflicting results.11,12 
disease activity score in 28 joints (DAS28) is a 
qualitative scale for evaluation of the disease 
activity and contains four parameters [frequency of 
swollen joints and joints with tenderness, 
erythrocyte sedimentation rate (ESR), and visual 
analog scale (VAS)] and calculated mathematically. 
Values less than 2.6 were considered as a response 
to treatment. Anti-CCP in severe forms of RA 
which can clearly be identified. DMARDs delay 
progression of the disease.13 
The present study aimed to investigate the 
effects of DMARDs in reducing serum anti-CCP. 
In fact it was designed and performed to address 
the possibility of if DMARDs interfere in RA 
pathology by reducing serum anti-CCP as well as 
application of anti-CCP for monitoring of the 
responses to DMARD therapy. 
Materials and Methods 
A cross-sectional study was performed on 30 RA 
patients who referred to the Clinic of 
Rheumatology in Towhid Hospital, Sanandaj, 
Iran. The serum anti-CCP was measured before 
and after treatment with DMARD group in RA 
patients. 
Duration of symptoms, morning stiffness, 
number of joints and hand joints involvement, 
symmetric joint involvement, radiological changes 
due to RA, rheumatoid nodules, serum RF, ESR, 
VAS, and anti-CCP and index disease severity scale 
(DAS28) were also measured and recorded at the 
beginning of study. From May 2009 to February 
2010 (8 months), 51 patients with a primary 
diagnosis of RA were referred to the rheumatology 
outpatient clinic. Patients who did not have an 
acceptable standard or whom refused of 
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complications were excluded from the study. 
Based on the American College of 
Rheumatology (ACR) criteria classification and 
clinical picture, 30 patients (22 women and 8 men) 
with diagnosis of RA were recruited. Treatment 
with DMARD group started at the beginning of 
the study. At the 1st and 6th month of the study, 
clinical findings, and disease activities were 
recorded and anti-CCP was measured. 
After giving a simple explanation to patients, a 
written consent was obtained. Patient characteristics 
including the initial signs and symptoms of the 
disease were recorded. Hand radiographies (by 
radiologists and rheumatologists) was undertaken 
and recorded according to SHARP score. 
Serum titration of anti-CCP and other tests 
were ordered and performed for free. To avoid 
errors and reducing the potential difference 
between the results of tests conducted in the 
laboratory, a standard kit was used. At the start of 
study DMARD, 7.5 mg prednisone daily, 
hydroxychloroquine 200 mg daily and oral 
methotrexate (10 mg/week) were prescribed. 
By using a checklist, the side effects and 
clinical examination were investigated and 
recorded. In 2 of 30 patients, methylprednisolone 
80 mg was injected intra-articular and in one 
patient methotrexate was increased to 15 mg 
weekly and hydroxychloroquine to 400 mg daily 
due to severe knee arthritis. 
Six months after taking DMARDs, serum anti-
CCP, ESR, C-reactive protein (CRP), RF, VAS, and 
hand radiographs were measured once again. 
Disease severity index DAS28 that shows the 
severity of pain and inflammation of the patients 
were calculated at the beginning and the end of 
the study. The DAS28 includes joint tenderness 
(0-28), number of swollen joints (0-28), and ESR. 
The VAS method was calculated by Excel 
software. This method is used for pain quality 
determination and is stated as a horizontal line 
from 0 to 10 cm long (0 means no pain and 10 
means the most intense pain felt by the patient). 
Of all 30 patients with RA, 10 cc of blood was 
taken and serum was separated for testing. 
Collected samples were transported as frozen to 
the Unity Center of Immunology Laboratory in 
hospital. RF was measured via latex agglutination 
method by using commercial kits Genesis® 
Company. An anti-CCP antibody was measured 
by using commercial kits Genesis® that measures 
anti-CCP antibody of IgG class. In this method, 
the ELISA microplates have been covered with 
recombinant citrullinated filagrin. 
Control samples with known concentration 
were also investigated to control the accuracy and 
reliability of standardized tests in parallel and the 
results were recorded. 
McNemar and Bhapkar’s test and Spearman 
Rank correlation test and Mann–Whitney test 
were used for data analysis. A probability value 
of 5% was statistically considered significant. 
Results 
Eligible patients for the present study were 30 
individuals including 22 females (74%) and 8 
males (26%). The mean age ± SD of subjects was 
48.9 ± 9.72 years. The morning stiffness for more 
than 1 h and involvement of three areas were, 28 
(93%) and 12 (40%), respectively. 
Involvement of hand joints at the beginning 
and end of the study was observed in 30 cases 
(100%). Involving counterparts joints at the 
beginning and end of the study were 28 (93%) 
and 3 (10%), respectively. The corresponding 
rates was 3 (10%) and 1 (3%) for nodule and 25 
(83%) and 9 (30%) for RF titer 1+ (P < 0.05). 
Mean and standard deviation of ESR’s serum 
levels at the beginning of study were 40.7 and 
30.59 and 10.50 ± 9.86 at the end of study. Median 
VAS score ± interquartile range (IQR) at the 
beginning and end of the study were 58.17 ± 20.06 
and 16.5 ± 8.92 respectively. Moreover, median 
DAS ± IQR at the beginning and end of the study, 
were 6.18 ± 0.94 and 3.17 ± 1.42, respectively. 
CRP was positive in 21 patients (70%) at the 
beginning and only in 12 patients (40%) at the end 
of the study (P < 0.007). A total of 30 (100%) 
patients had theirserum anti-CCP positive  
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Table 1. Comparison of American College of Rheumatology criteria in rheumatoid arthritis patients 
before and after treatment with disease-modifying anti-rheumatic drugs 
Variable At the beginning, number (%) At the end of 6th month, number (%) P 
Morning stiffness > 1 h 28 (93) 12 (40) < 0.001 
Involvement > 3 area 28 (93) 13 (43) < 0.001 
Involvement of hand joints 4 (100) 4 (13) < 0.001 
Involving of counterparts joints 28 (93) 3 (10) < 0.001 
Nodules 3 (10) 1 (3) 0.470 
RF+ 25 (83) 9 (30) < 0.001 
Radiologic changes 29 (96) 8 (26) < 0.001 
Statistical test: McNemar; RF: Rheumatoid factor 
 
beginning and end of the study was 127 and 25 
U/ml, respectively (P < 0.001). The mean ± SD of 
duration of symptoms until diagnosis was  
15.73 ± 13.41 weeks. The history and physical 
exams and supplementary laboratory tests were 
negative for all 30 patients. DAS28 as a measure 
of disease activity in 26 cases (86%) was more 
than 5.1 and in 4 cases (13%) was higher than 
3.1. These finding represent the severe and 
moderate rates of disease activity. At the end of 
study, 9 of 30 patients treated with the index 
DAS28 lower than 2.6. 
At the end of 6th month, a significant 
association was observed between low serum 
anti-CCP and low ESR, low CRP, lower VAS, 
and a decrease in DAS28 (P = 0.001). Majority of 
patients (97%) had an abnormal serum anti-CCP 
level while this proportion was 85% in RA 
(Tables 1-4). 
 
Table 2. Changes in Disease Activity Score in 28  
joints in rheumatoid arthritis patients before and after 
treatment with disease-modifying anti-rheumatic drugs 
At the beginning 
After 6 month 
Rem LDA MDA  HDA Total 
Rem 0 0 0 0 0 
LDA 0 0 0 0 0 
MDA 1 1 1 1 4 
HDA 8 11 5 2 26 
Total 9 12 6 3 30 
P < 0.001; Rem: Remission; LDA: Low dose activity;  
MDA: Moderate dose activity; HDA: High dose activity;  
Statistical test: Bhapkar’s test 
Table 3. Association between Disease Activity Score in 
28 joints and other parameters of disease activity in 
rheumatoid arthritis patients after 6th month 
Parameter Rho P 
RF 0.43 0.016 
ESR 0.30 0.081 
CRP 0.27 0.205 
VAS 0.002 0.521 
Radiologic changes 0.22 0.239 
Statistical test: Spearman Rank correlation test;  
RF: Rheumatoid factor; ESR: Erythrocyte sedimentation rate; 
CRP: C-reactive protein; Anti-CCP: Anti-citrullinated cyclic protein, 
VAS: Visual analogue acales 
 
Table 4. Association between anti-cyclic citrullinated 
peptide levels and positive rheumatoid factor before 
and after of treatment in rheumatoid arthritis patients 
Parameter RF− RF+ Anti-CCP+ Anti-CCP− Total 
RF− 5 0 - - 5 
RF+ 16 9 - - 25 
Anti-CCP+ - - 19 11 30 
Anti-CCP− - - 0 0 0 
P = 0.0002; Statistical test: McNemar; RF: Rheumatoid factor; 
P = 0.0025; Statistical test: McNemar; Anti-CCP normal: < 18 U/ml; 
Anti-CCP Abnormal: > 18 U/ml; Anti-CCP: Anti-cyclic itrullinated 
peptide 
Discussion 
In the present study, a clear reduction in the 
symptoms was observed and most patients 
showed a good response to treatment over 6 
months. These findings are consistent with other 
studies.12-14 
For all patients, the early indicators of disease 
activity were significantly decreased by treatment 
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reported similar findings. However, decreasing 
the DAS28 has not been mentioned in these 
studies.12-14 
For all 30 patients included in the present 
study, the anti-CCP had decreased significantly. 
In the Ronnelid et al. study a reduction in the 
serum anti-CCP on sulfasalazine was found at the 
1st year only.13 In the Mikuls et al. study, the RF 
level, but not the anti-CCP level was decreased 
significantly (P ≤ 0.010).14 Through, in the other 
study, serum IgM, but not anti-CCP was reduced 
significantly.15,16 
According to the entering criteria for the 
study, all patients had unusual serum anti-CCP 
at the beginning of the study. At the end of 
study, due to drug intake 10 patients became 
RF negative. But anti-CCP was detectable 
which reflects the greater specificity of the anti-
CCP. During the course of treatment, the RF in 
11 patients became negative, but serum anti-
CCP level was still higher than the normal 
values. 
At the beginning of study, none of patients 
were RF positive and anti-CCP was lower than 
normal, but in all 30 RA patients who had ACR87 
criteria, the anti-CCP levels were higher than 
normal. At the end of the study, there was only 
one positive RF with anti-CCP levels lower than 
normal. But at the same time in eight patients with 
positive RF, there was positive serum anti-CCP. 
These findings indicate a similar specificity (68%) 
and more sensitivity (89%) of RF compared with 
anti-CCP (P < 0.050), as shown in other reports.15-18 
This might be due to existing antibodies against 
heterogeneous citrulline or different epitopes of 
citrulline molecules. Every patient can produce 
antibodies of different affinity, while kits are used 
for identification anti-CCP in the laboratory, 
consisting limited antigens. 
The main limitation of this study was the 
presence of patients who were taking other 
drugs, and referred to different clinics. However, 
they were excluded from the study. Another 
limitation of the study was the small sample size 
due to time constraints. 
Conclusion 
Measurement of serum anti-CCP is a helpful 
index of treatment response and monitoring of 
treatment efficacy in patients with rheumatoid 
arthritis. Early indicators of disease activity 
could be significantly decreased by treatment 
with DMARD group. For patients with a 
suspected RA, along with clinical examination, 
measurement of anti-CCP levels and the positive 
rate is recommended. Anti-CCP measurement 
along with the physical exam and index DAS28 
can be useful as indicator in monitoring patients 
treated for rheumatoid arthritis. 
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